Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations andDisclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 3-day suspension order for the drug license of its store at Shanti Park-Mira Road, Maharashtra. The order was issued by the Food and Drug Administration, Mumbai, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on June 10, 2025. The company has disclosed a potential revenue loss of approximately Rs 1.50 lakhs due to this suspension. This is a routine regulatory disclosure under SEBI Listing Regulations, with the matter limited to a single store location.
The impact is negligible — a single store suspended for just 3 days with a possible revenue loss of only Rs 1.50 lakhs is immaterial to Medplus's overall operations. Shareholders are unlikely to see any meaningful effect on the stock price from this disclosure.